Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTH NASDAQ:GCTK NASDAQ:TTOO NYSEAMERICAN:VTAK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.12$0.16▼$1.57$763K4.024,068 shs254 shsGCTKGlucoTrack$5.45-3.5%$7.48$5.16▼$3,756.00$2.70M-0.24173,522 shs236,076 shsTTOOT2 Biosystems$0.11-0.9%$0.14$0.06▼$6.00$2.44M0.43581,750 shs291,803 shsVTAKCatheter Precision$0.22-5.5%$0.26$0.16▼$3.35$2.60M-0.724.52 million shs587,168 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%-99.40%-99.81%GCTKGlucoTrack-3.54%-11.09%-4.29%-44.61%-99.73%TTOOT2 Biosystems-0.95%-13.74%-19.65%+4.45%-97.95%VTAKCatheter Precision-5.51%-8.72%-38.90%-33.43%-94.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGCTKGlucoTrack0.287 of 5 stars0.02.00.00.02.80.80.0TTOOT2 Biosystems2.2729 of 5 stars3.05.00.00.00.00.00.0VTAKCatheter Precision0.2142 of 5 stars0.02.00.00.00.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/AGCTKGlucoTrack 0.00N/AN/AN/ATTOOT2 Biosystems 2.00Hold$5.004,251.61% UpsideVTAKCatheter Precision 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K0.00N/AN/A($2.43) per share0.00GCTKGlucoTrackN/AN/AN/AN/A($983.43) per shareN/ATTOOT2 Biosystems$7.68M0.31N/AN/A($6.91) per share-0.02VTAKCatheter Precision$420K5.85N/AN/A$1.33 per share0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98MN/A0.00N/AN/A-8,257.70%N/A-730.22%8/18/2025 (Estimated)GCTKGlucoTrack-$22.60M-$56.60N/A∞N/AN/AN/A-544.87%N/ATTOOT2 Biosystems-$50.08MN/A0.00∞N/A-563.16%N/A-174.06%7/28/2025 (Estimated)VTAKCatheter Precision-$16.64MN/A0.00N/AN/A-3,744.91%-153.90%-68.25%8/13/2025 (Estimated)Latest ARTH, GCTK, TTOO, and VTAK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GCTKGlucoTrackN/A-$20.40N/A-$0.67N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/AGCTKGlucoTrackN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/AVTAKCatheter PrecisionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01GCTKGlucoTrack0.034.854.85TTOOT2 BiosystemsN/A0.400.24VTAKCatheter PrecisionN/A0.210.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%GCTKGlucoTrack10.92%TTOOT2 Biosystems23.18%VTAKCatheter Precision20.34%Insider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%GCTKGlucoTrack12.91%TTOOT2 Biosystems0.03%VTAKCatheter Precision2.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableGCTKGlucoTrack5480,000416,000Not OptionableTTOOT2 Biosystems18021.04 million21.04 millionOptionableVTAKCatheter Precision1411.02 million10.69 millionN/AARTH, GCTK, TTOO, and VTAK HeadlinesRecent News About These CompaniesCatheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, FranceJuly 7, 2025 | finance.yahoo.comCatheter Precision, Inc. and Chelak iECG, Inc. Launch Joint Venture Kardionav for Advancements in Ventricular Tachycardia Ablation Technology - NasdaqJuly 2, 2025 | nasdaq.comCatheter Precision, Inc. Forms new Joint Venture Called Kardionav to Exploit patented AI Techniques to Create New VT Software platformJune 30, 2025 | finance.yahoo.comCatheter Precision, Inc. and Chelak iECG, Inc. Launch Joint Venture Kardionav for Advancements in Ventricular Tachycardia Ablation TechnologyJune 30, 2025 | quiverquant.comQCatheter Precision Inc News (VTAK) - Investing.comJune 28, 2025 | investing.comCatheter Precision, Inc. Addresses Increased Trading Activity in Common StockJune 12, 2025 | quiverquant.comQCatheter Precision, Inc. Comments on Recent Market ActivityJune 12, 2025 | globenewswire.comCatheter Precision (VTAK) Reports Key Progress for the LockeT ProductJune 12, 2025 | finance.yahoo.comCatheter Precision, Inc. Secures VIVO Purchase Order From Sahlgrenska University HospitalJune 9, 2025 | finance.yahoo.comCatheter Precision, Inc. Secures VIVO Purchase Order From Sahlgrenska University Hospital | ...June 9, 2025 | gurufocus.comCatheter Precision, Inc. Secures First Order for VIVO Product from Sahlgrenska University Hospital in SwedenJune 9, 2025 | quiverquant.comQCatheter Precision, Inc. Receives CE Mark Approval for LockeT, Expanding Market Opportunities in EuropeMay 27, 2025 | quiverquant.comQCatheter Precision, Inc. Receives CE Mark for LockeTMay 27, 2025 | globenewswire.comCatheter Precision Enters Market Offering AgreementMay 19, 2025 | tipranks.comCatheter Precision, Inc. Announces First Quarter 2025 Update and Financial ResultsMay 15, 2025 | finance.yahoo.comCatheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and ...May 12, 2025 | gurufocus.comCatheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic AllianceMay 12, 2025 | globenewswire.comCatheter Precision Finalizes Strategic Cardiac AcquisitionMay 8, 2025 | tipranks.comCatheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure AssetsMay 6, 2025 | finance.yahoo.comNew Clinical Data Presented about VIVO at the 46th Annual Heart Rhythm Association ConferenceMay 1, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeMP Materials Stock Booms on New Government PositioningBy Gabriel Osorio-Mazilli | July 14, 2025View MP Materials Stock Booms on New Government PositioningRocket Lab: Europe Comes Calling as Momentum BuildsBy Ryan Hasson | June 27, 2025View Rocket Lab: Europe Comes Calling as Momentum BuildsARTH, GCTK, TTOO, and VTAK Company DescriptionsArch Therapeutics OTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.GlucoTrack NASDAQ:GCTK$5.45 -0.20 (-3.54%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$5.53 +0.08 (+1.47%) As of 09:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.T2 Biosystems NASDAQ:TTOO$0.11 0.00 (-0.95%) As of 07/15/2025 03:44 PM EasternT2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Catheter Precision NYSEAMERICAN:VTAK$0.22 -0.01 (-5.51%) Closing price 07/15/2025 04:10 PM EasternExtended Trading$0.23 +0.01 (+3.14%) As of 09:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company sells it products through distribution partners, independent sales agents, and direct employees. Catheter Precision, Inc. is based in Fort Mill, South Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
